Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

VRPX

Virpax Pharmaceuticals Inc

Apr 24 • 04:00PM ET

3.17

Dollar change +0.01
Percentage change 0.32	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-12.97	Insider Own	25.72%	Shs Outstand	1.17M	Perf Week	-8.65%
Market Cap	3.71M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.87M	Perf Month	-16.71%
Income	-15.19M	PEG	-	EPS next Q	-	Inst Own	3.26%	Short Float	3.43%	Perf Quarter	4.38%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-18.04%	Short Ratio	1.22	Perf Half Y	-57.82%
Book/sh	1.65	P/B	1.92	EPS next Y	-	ROA	-103.68%	Short Interest	0.03M	Perf Year	-56.58%
Cash/sh	7.81	P/C	0.41	EPS next 5Y	-	ROE	-164.09%	52W Range	2.40 - 11.77	Perf YTD	-0.97%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-20.69%	ROI	-785.26%	52W High	-73.08%	Beta	1.48
Dividend TTM	-	Quick Ratio	1.25	Sales past 5Y	0.00%	Gross Margin	-	52W Low	31.97%	ATR (14)	0.39
Dividend Ex-Date	-	Current Ratio	1.25	EPS Y/Y TTM	29.85%	Oper. Margin	0.00%	RSI (14)	40.20	Volatility	12.09% 8.75%
Employees	7	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	20.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-52.74%	Payout	-	Rel Volume	0.19	Prev Close	3.16
Sales Surprise	-	EPS Surprise	-29.00%	Sales Q/Q	-	Earnings	Mar 26 BMO	Avg Volume	24.41K	Price	3.17
SMA20	-15.65%	SMA50	-15.23%	SMA200	-45.69%	Trades		Volume	4,656	Change	0.32%

Today 02:52PM	VRPX Stock Earnings: Virpax Pharmaceuticals Misses EPS for Q4 2023 (InvestorPlace)
Mar-26-24 07:30AM	Virpax Pharmaceuticals Reports 2023 Year-End Results (Business Wire)
Feb-27-24 07:31AM	Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaqs Minimum Bid Price (Business Wire) -14.59%
07:30AM	Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc. (Business Wire)
Feb-07-24 07:30AM	Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research (Business Wire) -8.11%
07:30AM	Loading…
Dec-29-23 07:30AM	Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting (Business Wire)
Nov-17-23 07:10AM	Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing (Business Wire)
07:00AM	Virpax Pharmaceuticals Announces Leadership Transition (Business Wire)
Nov-15-23 04:15PM	Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments (Business Wire) -7.25%
Oct-31-23 08:58AM	Virpax Pharmaceuticals Announces that Envelta Remains on Track for Trial in Humans Following FDA Review (Business Wire)
Oct-12-23 08:02AM	Virpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical Research (Business Wire) +5.10%
Oct-02-23 08:58AM	Gerald W. Bruce Appointed President and CEO of Novvae Pharmaceuticals (Business Wire)
Sep-27-23 08:58AM	Virpax Pharmaceuticals Announces Results of Probudur Dose Escalation Studies (Business Wire)
Sep-26-23 08:58AM	Virpax Pharmaceuticals to Present at the LD Micro Main Event XVI (Business Wire)
Sep-22-23 11:27AM	Lab Notes: Main Line firm spins off company that will focus on OTC product pipeline (American City Business Journals)
10:00AM	Loading…
Sep-21-23 10:00AM	Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses (Business Wire)
Sep-18-23 07:58AM	Virpax Pharmaceuticals Announces the Formation of Novvae Pharmaceuticals (Business Wire)
Sep-05-23 09:00AM	Virpax Pharmaceuticals Updates on Litigation (Business Wire)
Aug-28-23 08:58AM	Virpax® Pharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference (Business Wire)
Aug-14-23 09:00AM	Virpax Pharmaceuticals Reports 2023 Second Quarter Results and Recent Developments (Business Wire)
Aug-10-23 08:58AM	Virpax Pharmaceuticals Files Provisional Patent Application for NSAID Formulation and Method (Business Wire) +5.87%
Jul-24-23 07:00AM	Virpax Pharmaceuticals, Inc. to Ring NASDAQ Closing Bell on July 24, 2023 (Business Wire)
Jul-13-23 08:58AM	Virpax Pharmaceuticals Files Provisional Patent Application for Intranasal Delivery (Business Wire)
Jun-21-23 08:00AM	Virpax Pharmaceuticals Enters into CRADA with the National Advisory Neurological Disorders and Stroke Council (Business Wire)
Jun-20-23 04:10PM	Virpax Pharmaceuticals Announces CFO Transition (Business Wire) -8.33%
Jun-13-23 08:58AM	Virpax Pharmaceuticals to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET (Business Wire)
May-12-23 04:08PM	Virpax Pharmaceuticals Reports 2023 First Quarter Results and Recent Developments (Business Wire)
May-10-23 07:15AM	Virpax Pharmaceuticals To Present at Upcoming CB Tech Watch Seminar (Business Wire) +6.01%
May-09-23 07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
May-04-23 08:58AM	Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference May 10-11, 2023 (Business Wire)
03:30PM	Loading…
May-02-23 03:30PM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE) -5.31%
Apr-27-23 08:58AM	Virpax Pharmaceuticals Engages Dr. Pardeep Gupta to Assist in Development of Companys Lead Asset, Probudur (Business Wire)
Apr-05-23 08:58AM	Virpax Reports on Progress of Envelta (Business Wire)
Mar-28-23 08:58AM	Virpax Pharmaceuticals Announces Appointment of Barbara A. Ruskin, Ph.D, J.D. to the Board of Directors (Business Wire)
Mar-22-23 08:58AM	Virpax Pharmaceuticals Reports 2022 Year-End Results (Business Wire)
Feb-13-23 08:58AM	Virpax Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology (MET) (Business Wire)
Jan-31-23 08:58AM	Virpax Pharmaceuticals Engages New England Investors to Direct Licensing Strategy for Envelta in China (Business Wire) +22.20%
Jan-18-23 09:00AM	Virpax Pharmaceuticals to Utilize Dr. Neil K. Singla to Assist in Development of Probudur (Business Wire)
Jan-10-23 09:00AM	Virpax Pharmaceuticals Engages Destum Partners to Direct Strategic Global Partnering Efforts (Business Wire)
Jan-04-23 09:00AM	Virpax Pharmaceuticals Engages Dr. Kenneth W. Sommerville and Dr. Lawrence Fried to Assist in Development of NobrXiol (formerly VRP324) (Business Wire) +10.45%
Dec-14-22 09:00AM	Virpax Pharmaceuticals Reports on FDA Pre-IND Response for NobrXiol (formerly VRP324) (Business Wire) -7.15%
Nov-09-22 09:00AM	Virpax Pharmaceuticals Reports 2022 Third Quarter Results (Business Wire)
Oct-13-22 06:29AM	Quite a few insiders invested in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) last year which is positive news for shareholders (Simply Wall St.)
Aug-24-22 09:00AM	Dr. Jeffrey Gudin, Chief Medical Officer of Virpax Pharmaceuticals, to Present Poster at World Congress of World Institute of Pain (Business Wire)
Aug-15-22 09:00AM	Virpax Pharmaceuticals Reports 2022 Second Quarter Results and Recent Developments (Business Wire)
Jul-22-22 11:32AM	15 Philadelphia-area Black executives listed among the most influential in corporate America by Savoy (American City Business Journals)
Jul-05-22 09:00AM	Virpax Pursues OTC Medical Device Pathway for AnQlar (Business Wire)
Jul-01-22 04:04PM	These summer travel destinations are on sale right now (Yahoo Finance Video)
06:33AM	Airbnbs British Invasion Faces Potential Backlash (The Wall Street Journal)
Jun-30-22 06:44AM	Why the latest round of tech layoffs feels a bit different (Yahoo Finance)
04:00AM	Airbnb: Could a Recession Take Air Out of the Stock? (TipRanks)
Jun-29-22 04:06PM	Travel sector: Staffing shortages have had a ripple effect, ETF expert says (Yahoo Finance Video) +6.37%
11:30AM	Chip stocks fall, cruise stocks weigh on travel sector, Peloton stock touches new low (Yahoo Finance Video)
09:32AM	JPMorgan downgrades Amazon, Meta, and 24 other tech company stocks (Yahoo Finance Video)
Jun-28-22 07:08PM	Short-term lets face stricter rules as review gauges impact on tourist hotspots (Financial Times)
05:01PM	Airbnb makes temporary party ban permanent (American City Business Journals)
04:37PM	Airbnb Makes Its Ban on Parties Permanent (The Wall Street Journal)
11:14AM	Airbnb bans parties, Sheetz cuts gas prices through 4th of July, Serena Williams returns to Wimbledon (Yahoo Finance Video)
Jun-27-22 12:13PM	Chester County pharma firm pivots to OTC strategy for experimental pain drug (American City Business Journals)
09:00AM	Virpax Will Pursue Direct to OTC Pathway for Epoladerm for Pain Associated with Osteoarthritis (Business Wire)
Jun-24-22 12:25PM	Expedia, Airbnb, and Booking Holdings Could See a Travel Slump (Barrons.com)
Jun-23-22 04:34PM	Early Money: This startup wants to help small businesses crib from Airbnb and Netflix and run successful feature tests (American City Business Journals)
04:00AM	Airbnb is giving homeowners $100,000 to build wacky rentals (Quartz)
May-19-22 09:00AM	Virpax Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference (Business Wire)
May-16-22 09:00AM	Virpax Pharmaceuticals Reports 2022 First Quarter Results and Recent Developments (Business Wire)
May-06-22 06:12AM	A number of insiders bought Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) stock last year, which is great news for shareholders (Simply Wall St.) -7.45%
May-05-22 09:00AM	Virpax Pharmaceuticals Enters Into CRADA With The U.S. Army Institute of Surgical Research (Business Wire)
Apr-26-22 09:00AM	Virpax Successfully Completes Initial Preclinical Studies for VRP324 (Business Wire)
Mar-31-22 09:00AM	Virpax Pharmaceuticals Reports 2021 Year-End Results (Business Wire)
Mar-22-22 09:00AM	Virpax Completes All FDA-Required Pre-Clinical Studies for Epoladerm (Business Wire) +9.05%
04:00AM	Nanomerics Receives Further Upfront Payment for Anti-Viral Spray AnQlar(TM) (ACCESSWIRE)
Mar-15-22 01:45PM	Virpax Pharma Expands AnQlar Worldwide Licensing Pact In COVID-19 (Benzinga) +5.79%
10:06AM	Virpax shares rise on expanded licensing deal for experimental drug (American City Business Journals)
09:00AM	Virpax Pharmaceuticals Expands AnQlar Development and Commercialization Rights Through Worldwide Licensing Agreement (Business Wire)
Feb-15-22 09:00AM	News Outlets Highlight Virpax Pharmaceuticals and Its Potential Solutions for the Opioid Crisis and COVID-19 (Business Wire) +8.45%
Feb-10-22 09:00AM	Virpax Reports Favorable Preclinical Safety Data for Envelta for the Treatment of Acute and Chronic Pain (Business Wire)
Jan-21-22 11:00AM	Altasciences Chosen by Virpax Pharmaceuticals, Inc. to Conduct First-in-Human Study of Epoladerm for Chronic Pain Associated with Osteoarthritis of the Knee (Business Wire) -12.88%
Jan-18-22 09:00AM	Virpax® Successfully Completes Preclinical Dermal Safety Studies for Epoladerm (Business Wire)
Jan-04-22 09:20AM	Virpax® Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference (Business Wire) -6.37%
Dec-28-21 08:00AM	Virpax Pharmaceuticals Recaps Milestones and Highlights Product Portfolio (Business Wire) -5.22%
Dec-20-21 08:00AM	Virpax Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm for Pain Associated with Osteoarthritis of the Knee (Business Wire)
Dec-08-21 08:00AM	Virpax Reports Successful Results of Toxicology and Pharmacokinetic Study for Epoladerm (Business Wire) +10.12%
Dec-01-21 07:16AM	Top 10 Stock Picks of Hal Mintzs Sabby Capital (Insider Monkey) -7.91%
Nov-27-21 08:04AM	Trade Alert: The Chairman & CEO Of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX), Anthony Mack, Has Just Spent US$100k Buying 17% More Shares (Simply Wall St.)
Nov-15-21 08:00AM	Virpax Pharmaceuticals Reports 2021 Third Quarter Results and Recent Developments (Business Wire)
Nov-10-21 08:00AM	Virpax Advances Envelta Development with NCATS Under CRADA Agreement (Business Wire) -5.24%
Oct-20-21 07:00AM	Recro Awarded Development and Manufacturing Contract by National Institutes of Health (NIH) to Support Novel Nasal Spray Analgesic (GlobeNewswire)
Oct-06-21 09:00AM	Virpax Signs Agreement with Sinclair Research to Initiate Investigational New Drug (IND)-Enabling Studies for AnQlar (Business Wire)
Oct-01-21 08:00AM	Virpax to Present at the NobleCon Online Pain Management Investor Forum on Channelchek.com on October 7, 2021 (Business Wire)
Sep-20-21 09:00AM	Virpax to Develop Intranasal Cannabidiol Product for the Management of Epilepsy in Adults and Children (Business Wire) -9.06%
Sep-16-21 01:00PM	Virpax® Pharmaceuticals Announces Closing of $40 Million Public Offering of Common Stock (Business Wire)
Sep-14-21 02:49PM	Mid-Afternoon Market Update: Dow Tumbles 300 Points; Communications Systems Shares Climb (Benzinga) -36.82%
12:27PM	Mid-Day Market Update: FuelCell Energy Jumps After Q3 Results; RedHill Biopharma Shares Slide (Benzinga)
10:11AM	Mid-Morning Market Update: Markets Mostly Lower; US Annual Inflation Rate Slows to 5.3% in August (Benzinga)
09:05AM	Virpax® Pharmaceuticals Announces Pricing of $40 Million Public Offering of Common Stock (Business Wire)
Sep-13-21 07:07AM	21 Stocks Moving in Monday's Pre-Market Session (Benzinga) -15.95%
Sep-02-21 09:00AM	Virpax Pharmaceuticals Announces Poster Presentation for Envelta at PAINWeek 2021 (Business Wire)
Aug-26-21 02:51PM	Why Virpax Pharmaceuticals Stock Is Trading Higher Today (Benzinga)
09:00AM	Virpax Announces MMS019 Manufacturing and Supply Agreement (Business Wire)
Aug-19-21 07:07AM	21 Stocks Moving in Thursday's Pre-Market Session (Benzinga) -24.80%

Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. Its products include metered-dose spray, liposomal gel encapsulates, and intranasal spray. The company was founded by Anthony P. Mack and Jeffrey A. Gudin in 2016 and and is headquartered in Berwyn, PA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VRPX

Virpax Pharmaceuticals Inc

Upgrade your FINVIZ experience